© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
August 04, 2011
Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.
Patients with anthracycline-treated sarcomas had a 3-fold improvement in PFS with antiangiogenic agent pazopanib versus placebo.
August 03, 2011
An exploratory analysis of the phase III EMBRACE trial of eribulin mesylate in metastatic breast cancer found the survival benefit and toxicity profile to be independent of age.
Patients with metastatic soft-tissue sarcoma had statistically significant improvement in PFS when treated with mTOR inhibitor ridaforolimus.
Patients with operable gastric cancer had significant improvement in DFS with adjuvant capecitabine plus Xelox following definitive surgery.
August 02, 2011
Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.
Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.
PFS improved significantly in patients with EGFR-mutated advanced NSCLC treated first line with erlotinib versus platinum-based chemotherapy.
August 01, 2011
Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.
A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.
July 29, 2011
The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.
July 28, 2011
Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.
Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.
July 27, 2011
Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.
July 26, 2011
Adding oxaliplatin to 5-fluorouracil before and after surgery for the treatment of locally advanced rectal cancer is demonstrating significant benefit.
July 25, 2011
In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.
July 22, 2011
Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.
July 21, 2011
The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.
July 20, 2011
Although once considered a promising drug for lung cancer and other tumor types, motesanib added to carboplatin/paclitaxel chemotherapy did not improve overall survival.